The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical characteristics of nivolumab-induced radiation recall pneumonitis in patients with non-small cell lung cancer: A multicenter real-world analysis of 669 patients.
 
Tadasuke Shimokawaji
Honoraria - AstraZeneca; Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Shoko Narita
No Relationships to Disclose
 
Tomoyuki Naito
No Relationships to Disclose
 
Hibiki Udagawa
Honoraria - Abbvie; Amco; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
Research Funding - Abbvie; Amgen; Daiichi Sankyo; MSD
 
Koichi Goto
Honoraria - AbbVie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Life Technologies; Lilly; Merck Serono; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Quintiles; RIKEN GENESIS; SRL Diagnostics; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; Loxo; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Riken Genesis; RTI Health Solutions; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Xcoo
 
Taichi Miyawaki
No Relationships to Disclose
 
Nobuaki Mamesaya
No Relationships to Disclose
 
Kazuhisa Nakashima
No Relationships to Disclose
 
Hirotsugu Kenmotsu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst)
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; Roche; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Chugai Pharma; Lilly; Merck Serono; MSD; Nitto Denko; Pfizer
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Kyorin; Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron; Taiho Pharmaceutical (Inst)
 
Taiki Hakozaki
No Relationships to Disclose
 
Yusuke Okuma
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis
Research Funding - Chugai Pharma; takeda (Inst)
 
Masaki Nakamura
Consulting or Advisory Role - MSD K.K
 
Yuko Nakayama
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca
 
Hirokazu Watanabe
Research Funding - Fujifilm (Inst)
 
Masahiko Kusumoto
Honoraria - AstraZeneca Japan; MSD K.K; Ono Pharmaceutical
Research Funding - Canon Medical System
 
Yuichiro Ohe
Stock and Other Ownership Interests - Ono Pharmaceutical (I)
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Ignyta (Inst); Kyorin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Expert Testimony - AstraZeneca; Ono Pharmaceutical
 
Hidehito Horinouchi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; Novartis
Research Funding - A2 Healthcare (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genomic Health (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)